BARCELONA,Spain - February 05, 2024 - Omniscope Inc. today announced it has joined NVIDIA Inception, a program that nurtures startups revolutionizing industries with technological advancements.
Omniscope is focused on building the world’s largest and most complete immune databank. Through the convergence of proprietary immune cell sequencing and AI,Omniscope decodes the immune system in high resolution to inform therapy and develop diagnostics.
Omniscope plans to use the resources available through NVIDIA Inception, including cloud credits, technology discounts, and technical training, to accelerate the development of its AI models, scale its products, and move a step closer toward fulfilling its mission of bringing healthcare to everyone, everywhere. The program will also offer Omniscope the opportunity to collaborate with industry-leading experts and other AI-driven organizations.
“Joining NVIDIA Inception marks a pivotal moment for Omniscope as we embark on a transformative journey to decode the immune system in unprecedented detail. The program provides us with invaluable resources, propelling our AI-driven mission to build the world’s largest immune databank and bringing us closer to our vision of universal healthcare accessibility. Participating in NVIDIA Inception aligns seamlessly with our commitment to pushing the boundaries of health and science, and we are excited to leverage the program’s support to revolutionize the future of healthcare for everyone, everywhere,” said Vijay Vaswani, OmniscopeCo-founder & CEO.
NVIDIA Inception helps startups during critical stages of product development, prototyping, and deployment. Every Inception member gets a custom set of ongoing benefits, such as NVIDIA Training credits, preferred pricing on NVIDIA hardware and software, and technological assistance, which provides startups with the fundamental tools to help them grow.
Omniscope is decoding the immune system in high resolution.The company is building the world’s largest and most complete immune databank. Its vertically integrated platform powers groundbreaking therapeutic designs and diagnostic development.